Clinical impact and prognosis of patients with Si-NET and bone metastases – Do they matter?

#4133

Introduction: The prevalence of bone metastases (BM) in small intestinal neuroendocrine tumors (Si-NET) ranges from 5 to 23 %.

Aim(s): The aim of our study was to evaluate the overall survival (OS) and the associated symptoms, in particular bone-related pain and fractures in Si-NET patients with BM, which previously have been sparsely described.

Materials and methods: This is a retrospective cohort study between 1st of January 2010 and 20th of March 2023. We included 133 Si-NET patients with BM detected at 68Gallium-DOTATOC-octreotate PET/CT (68Ga-SSA-PET/CT). Patients were treated and followed at a tertiary referral hospital in Sweden; Uppsala University Hospital. Patients’ characteristics were collected including data on BM-related symptoms, fractures and treatment with analgetics due to bone-related pain. Patients were divided into two groups, those with 1-5 BM or > 5 BM.

Conference:

Presenting Author: Wedin M

Authors: Wedin M, Daskalakis K, Tiensuu Janson E, Sundin A, Wallin G,

Keywords: bone metastases, si-net, Neuroendocrine Neoplasm,